Talecris stock slips as demand for blood-plasma products wane

12/1/2009 | News & Observer (Raleigh, N.C.), The

Shares of Talecris, a maker of blood plasma-derived treatments for various immune disorders, dropped Monday by almost 20% since reaching a high in early November, amid concerns that the company won't be able to sustain its rising profit into the coming year. Analysts say the economic downturn could create an oversupply in blood-plasma products as more people donate.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health